ADVANTAGES OF PEMBROLIZUMAB IN THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
There are several effective treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (PRGS). Inhibitors of immune control points at the stage of clinical trials showed a lower level of toxicity against the background of an adequate anti-tumor response compared with drugs of the standard treatment regimen. The pembrolizumab complex with chemotherapy may be recommended for the treatment of malignant neoplasms of the head and neck with lower PD-L1 expression, and monotherapy with pembrolizumab is proposed for the treatment of PD-L1-positive PRGS.